Supply Chain

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

The Federal Trade Commission and the Department of Health and Human Services are seeking public input to evaluate how policymakers can address chronic drug shortages and promote a resilient supply chain.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

In this video interview with Associate Editor Miranda Schmalfuhs, Dr. Jo Varshney, CEO & Founder of VeriSIMLife, discusses how artificial intelligence and machine learning can assist in the drug shortage problem.

RLG Healthcare will focus on specialty pharmaceuticals and healthcare packaging.

A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.

The pharma powerhouse is investing $300 million in a plant that could be vital for the future cancer trials.

DB Schenker, JAS, Medista, MSC Air Cargo, OnAsset Intelligence, and xpd global round out the latest additions.

The air cargo market numbers close out the year slightly below 2022’s performance.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

In order to provide both profitability and medication access, a balancing act is required.

A look at the challenges that need to be addressed during the FDA stabilization period.

Under the DSCSA law, wholesale distributors, re-packagers, dispensers, and other third-party logistics providers must implement interoperable and electronic tracing of prescription products at the package level.

As a result, time to treatment for the brand Gilead product is expected to increase from 16 to 14 days.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

One lot of the company’s branded dextroamphetamine sulfate tablets is being removed from shelves nationwide due to a pharmacy receiving carbinoxamine maleate instead.

The predicted value is largely driven by manufacturers' prioritization of brand protection.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

IATA’s latest numbers suggest the strongest year-on-year growth in almost two years.

The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.

Review article explores the latest developments surrounding expression and purification strategies.

The latest move expands the company’s storage capacity and cold chain capabilities.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.